A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio® ) in cardiac surgery: the REVAKI-1 study.

Arne RingTom MorrisMarcin WozniakNikol SulloWilliam DottVeerle VerheydenTracy KumarNigel BrunskillRakesh VajaGavin J Murphy

Published in: British journal of clinical pharmacology (2016)

Pharmacokinetics of sildenafil during cardiopulmonary bypass were comparable to those of other patient groups. The drug was well tolerated at therapeutic plasma levels. These results support the further evaluation of sildenafil for the prevention of AKI in cardiac surgery.

Keyphrases

cardiac surgery
acute kidney injury
pulmonary hypertension
pulmonary arterial hypertension
randomized controlled trial
study protocol